Amgen and Allergan's Biosimilar to Rituxan Looks Good in Phase I/III Trial - BioSpace

Amgen and Allergan's Biosimilar to Rituxan Looks Good in Phase I/III Trial  BioSpace

Amgen and Allergan announced positive top-line results from a Phase I/Phase III trial of their biosimilar candidate, ABP 798, to Genentech and Biogen's Rituxan ...